To promote its newly launched nonhormonal menopause drug, Bayer is linking Lynkuet with a familiar face.

Even in the era of the FDA’s Commissioner’s National Priority Voucher program, Jazz Pharmaceuticals is showing that traditional priority review vouchers can catch a pretty penny.

As part of its mission to make a dent in the sizable presbyopia market, Lenz Therapeutics has scoped out a star-studded partnership for its Vizz prescription eye drops.

Much is riding on Travere Therapeutics’ bid to gain an expansion for Filspari to treat focal segmental glomerulosclerosis (FSGS). The indication represents a $2 billion peak sales opportunity in the U.S. alone, according to Leerink Partners. So it was with some trepidation that Travere revealed that the FDA has postponed […]

Amneal Pharmaceuticals and VantAI have joined the ranks of companies to decide a new year demands a new look, each unveiling fresh branding aligned with their respective plans for 2026.

Leo Pharma CEO Christophe Bourdon is eager to make additional strides on the new era of growth he’s fostered since taking over in 2022, he said in an interview on the sidelines of the J.P. Morgan Healthcare Conference.